ETF Holdings Breakdown of CRSP

Stock NameCrispr Therapeutics AG
TickerCRSP(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINCH0334081137
LEI506700O6IRRIQLT3W370

News associated with CRSP

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $69.53 Average Target Price from Analysts
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have earned a consensus recommendation of “Hold” from the seventeen brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and nine have issued a buy recommendation on the company. […] - 2025-06-24 05:54:46
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Farther Finance Advisors LLC
Farther Finance Advisors LLC lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 46.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,626 shares of the company’s stock after purchasing an additional 1,792 […] - 2025-06-20 07:29:03
California State Teachers Retirement System Sells 689 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
California State Teachers Retirement System lowered its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,742 shares of the company’s stock after selling 689 shares during the period. California State […] - 2025-06-06 08:06:55
Two Sigma Advisers LP Increases Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Two Sigma Advisers LP lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 50.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 84,800 shares of the company’s stock after acquiring an additional 28,400 shares during the period. Two Sigma Advisers LP’s holdings in CRISPR Therapeutics were worth $3,338,000 as of […] - 2025-05-27 08:30:57
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Moderate Buy” by Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and ten have assigned a buy recommendation […] - 2025-05-27 06:06:46
Ameriprise Financial Inc. Has $8.07 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
Ameriprise Financial Inc. lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 205,173 shares of the company’s stock after acquiring an additional 18,412 shares during the period. Ameriprise Financial Inc.’s holdings in CRISPR Therapeutics were worth $8,072,000 as of its most recent […] - 2025-05-22 07:35:07
BNP Paribas Financial Markets Has $3.27 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
BNP Paribas Financial Markets decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 82,994 shares of the company’s stock after selling 4,962 shares during the quarter. BNP […] - 2025-05-16 08:08:54
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Decreased by Mercer Global Advisors Inc. ADV
Mercer Global Advisors Inc. ADV lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 13.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,980 shares of the company’s stock after selling 1,598 shares during […] - 2025-05-15 08:10:56
Barclays Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target lowered by Barclays from $56.00 to $42.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an equal weight rating on the stock. Several other equities analysts have also recently commented on the stock. Truist Financial boosted their price […] - 2025-05-12 08:46:49
Dimensional Fund Advisors LP Has $37.28 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
Dimensional Fund Advisors LP boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 14.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 947,301 shares of the company’s stock after purchasing an additional 122,695 shares during the quarter. Dimensional […] - 2025-05-05 08:20:52
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Hold” by Analysts
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have received an average rating of “Hold” from the twenty-one research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have issued a buy recommendation on […] - 2025-05-02 07:20:50
CRISPR Therapeutics AG (NASDAQ:CRSP) Position Raised by NewEdge Advisors LLC
NewEdge Advisors LLC grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 28.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 7,420 shares of the company’s stock after purchasing an additional 1,622 shares during the quarter. NewEdge Advisors LLC’s […] - 2025-05-01 08:37:08
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Invesco Ltd.
Invesco Ltd. raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,790 shares of the company’s stock after purchasing an additional 2,010 shares during the period. Invesco Ltd.’s holdings in CRISPR […] - 2025-05-01 07:42:52
Raymond James Financial Inc. Invests $3.23 Million in CRISPR Therapeutics AG (NASDAQ:CRSP)
Raymond James Financial Inc. bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 82,095 shares of the company’s stock, valued at approximately $3,231,000. A number of other institutional investors […] - 2025-04-28 07:51:03
Legal & General Group Plc Has $3.85 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Legal & General Group Plc trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 8.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 97,804 shares of the company’s stock after selling 9,121 shares during the quarter. Legal & General […] - 2025-04-23 08:19:07
Wells Fargo & Company MN Buys 17,094 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Wells Fargo & Company MN increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 220,123 shares of the company’s stock after purchasing an additional 17,094 shares during the quarter. Wells Fargo & […] - 2025-04-18 07:36:51
Geode Capital Management LLC Sells 7,346 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Geode Capital Management LLC lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 0.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,000,868 shares of the company’s stock after selling 7,346 shares during the period. Geode Capital Management LLC’s holdings in CRISPR Therapeutics were worth $39,412,000 as of its […] - 2025-04-16 07:38:58
Norges Bank Makes New $17.46 Million Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)
Norges Bank acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 443,536 shares of the company’s stock, valued at approximately $17,458,000. Norges Bank owned about 0.52% of CRISPR Therapeutics as of its most recent filing with […] - 2025-04-08 08:19:03
Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.6% in the fourth quarter, HoldingsChannel reports. The firm owned 5,252 shares of the company’s stock after buying an additional 372 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in CRISPR Therapeutics […] - 2025-04-04 08:12:57
KLP Kapitalforvaltning AS Buys New Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
KLP Kapitalforvaltning AS purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 16,100 shares of the company’s stock, valued at approximately $634,000. A number of other large investors have also bought and sold shares of the stock. Charles Schwab Investment […] - 2025-04-03 07:28:56
Congress Wealth Management LLC DE Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Congress Wealth Management LLC DE purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 5,640 shares of the company’s stock, valued at approximately $222,000. Several other hedge funds also recently added to or reduced their […] - 2025-03-31 08:15:00
Corient Private Wealth LLC Has $347,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 8,827 shares of the company’s stock after selling 365 shares during the period. Corient Private Wealth LLC’s holdings in CRISPR Therapeutics were worth $347,000 as of its most recent […] - 2025-03-31 07:30:54
Avantax Advisory Services Inc. Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)
Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,836 shares of the company’s stock, valued at approximately $269,000. A number of other institutional investors have also modified their […] - 2025-03-26 08:50:59
Harbour Investments Inc. Sells 350 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,717 shares of the company’s stock after selling 350 shares during the period. Harbour Investments Inc.’s […] - 2025-03-24 08:39:11
Zurcher Kantonalbank Zurich Cantonalbank Has $874,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 22,217 shares of the company’s stock after acquiring an additional 645 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in CRISPR […] - 2025-03-21 09:18:55
Farther Finance Advisors LLC Acquires 977 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Farther Finance Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,834 shares of the company’s stock after purchasing an additional 977 shares during the period. Farther Finance […] - 2025-03-21 08:27:02
US Bancorp DE Sells 1,380 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
US Bancorp DE lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 53.3% during the 4th quarter, Holdings Channel reports. The firm owned 1,209 shares of the company’s stock after selling 1,380 shares during the period. US Bancorp DE’s holdings in CRISPR Therapeutics were worth $48,000 at the end of […] - 2025-03-19 07:10:48
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Hold” by Analysts
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from the twenty-one ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating […] - 2025-03-13 06:53:04
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 10.8% during the 4th quarter, Holdings Channel reports. The fund owned 44,692 shares of the company’s stock after acquiring an additional 4,351 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings […] - 2025-02-26 08:31:02
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.7% Following Insider Selling
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and last traded at $45.65. Approximately 914,670 shares traded hands during mid-day trading, a decline of 62% from the average daily volume […] - 2025-02-26 06:24:52

CRSP institutional holdings

The following institutional investment holdings of CRSP have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 52,729USD 2,462,444
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 14,193USD 662,813
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 43,098USD 2,012,677
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 43,098USD 2,012,677
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 348USD 16,252
Total =153,466 USD 7,166,863
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.